幽门螺杆菌感染后食管及近端胃癌发生率低
本研究基于美国退伍军人事务部36 803例确诊幽门螺杆菌感染患者(中位年龄60.4岁,91.8%男性)的回顾性队列,评估未来食管及近端胃癌发生率及危险因素。结果显示感染后5、10、15年累积发生率分别为0.145%、0.26%、0.34%,年龄增长和吸烟与癌症风险相关,而亚洲或夏威夷原住民种族具有保护作用,幽门螺杆菌治疗及根除状态与癌症无关。
要点
- 幽门螺杆菌感染后食管及近端胃癌15年累积发生率仅0.34%。
- 年龄增长和吸烟是未来食管及近端胃癌的危险因素。
- 幽门螺杆菌治疗或根除状态与未来癌症风险无关。
核心结论
- 在美国幽门螺杆菌感染患者中,食管及近端胃癌发生率低。
- 年龄增长和吸烟与未来癌症风险增加相关,亚洲或夏威夷原住民种族具有保护作用。
- 幽门螺杆菌治疗及根除状态与未来食管及近端胃癌无关。
主要发现
- 幽门螺杆菌检测后5、10、15年食管及近端胃癌累积发生率分别为0.145%、0.26%、0.34%。
- 与白人相比,非洲裔美国人(SHR 0.87,95%CI 0.57-1.43)和美国印第安人(SHR 1.31,95%CI 0.18-9.60)风险相似,亚洲人(213例中无病例)和夏威夷原住民(295例中无病例)风险显著降低(P < .001)。
- 年龄每增加5岁(SHR 1.17,95%CI 1.09-1.25,P < 0.001)和吸烟(SHR 2.06,95%CI 1.33-3.18,P = 0.001)与食管及近端胃癌风险相关。
- 幽门螺杆菌治疗或根除状态与癌症风险无关(P > 0.20)。
临床怎么用
- 对于幽门螺杆菌感染患者,食管及近端胃癌风险低,无需过度担心。
- 应关注高龄和吸烟患者,加强监测。
- 幽门螺杆菌治疗及根除不增加未来食管及近端胃癌风险。
局限性
- 回顾性队列研究,可能存在未测量的混杂因素。
- 研究人群以男性退伍军人为主,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Helicobacter pylori infection is the most important risk factor for non-proximal gastric adenocarcinoma, yet some posit it is protective against oesophageal adenocarcinoma and proximal gastric cancers. AIMS: To evaluate the incidence of and risk factors for future oesophageal and proximal gastric cancers, utilizing the largest North American cohort of patients with previously identified H pylori. Also to identify whether treatment and eradication of H pylori alter future oesophageal and proximal gastric cancer risk. METHODS: Retrospective cohort study within the Veterans Administration of 36 803 patients (median age 60.4 years; 91.8% male) with confirmed H pylori between 01 January 1994 and 31 December 2018. Primary outcome was diagnosis of future oesophageal and proximal gastric cancers. A time to event with competing risk analysis was performed, evaluating patient factors and whether the patient received H pylori treatment. Secondary analysis of those treated evaluated whether confirmed eradication was associated with cancer. RESULTS: The cumulative incidence of oesophageal and proximal gastric cancers 5, 10 and 15 years after H pylori detection was 0.145%, 0.26% and 0.34%. Risk of future oesophageal or proximal gastric cancer was similar amongst whites (reference), African Americans (SHR 0.87, 95%CI 0.57-1.43) and American Indians (SHR 1.31, 95%CI 0.18-9.60) but substantially reduced in those of Asian (no cases amongst 213 H pylori positive) or native Hawaiian origin (no cases amongst 295 H pylori positive) (P < .001). Increasing age (SHR 1.17 per 5 years, 95% CI: 1.09-1.25, P < 0.001) and smoking (SHR 2.06, 95% CI: 1.33-3.18, P = 0.001) were associated with oesophageal and proximal gastric cancers. Neither treatment of H pylori nor eradication status were associated with cancer (P > 0.20). CONCLUSIONS: In the largest study of US patients with H pylori, we demonstrate that rates of oesophageal and proximal gastric cancers after treatment of H pylori are low. Older age, and smoking are associated with future cancer, whilst Asian or Native Hawaiian race are protective. H pylori treatment and eradication are not associated with future cancer.
引用
- Kumar S, Metz DC, Ginsberg GG, et al. Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection. Aliment Pharmacol Ther. 2020. PMID: 32133681. doi:10.1111/apt.15677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。